Neoplasms

Digestive System Diseases

All Conditions

Symptoms and General Pathology

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Rare Diseases

Esophageal Neoplasms

Hemorrhage

Body Weight

Lung Neoplasms

Thromboembolism

Venous Thromboembolism

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Bone Density Conservation Agents

Anti-Infective Agents

Amino Acids

Heparin

Calcium

Calcium heparin

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Calcium, Dietary

PENTA

Fondaparinux

Nadroparin

Hormones

Factor Xa Inhibitors

Antithrombins

Antithrombin III

Protease Inhibitors

Serine Proteinase Inhibitors

HIV Protease Inhibitors

Enzyme Inhibitors

Serine

use LMWH twice daily after lung resection

use Fondaparinux once daily after lung resection

use Fondaparinux once daily after esophagectomy

Nadroparin Calcium

4100AxaIU IH q12h(8Am,8Pm) after operation

Lizhen Xuan

The purpose of this study is to determine whether the use of different dose of LMWH compared with fondaparinux for thromboprophylaxis is efficacious and safety after thoracic surgery.

The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery

1.5ml aterial blood sample will be obtained daily for TEG , and the vulues of TEG,such as R,K,Alpha angle,MA,G,CI ,will be measured

all drain from chest tube are gathered and hematocrits are measured to calculate the quantities of bleeding

incidence of DVT is measured by vascular ultrasonography

the number of death in the period of hospital stay

Shanghai Zhongshan Hospital

department of anesthesiology and surgical intensive care unit

Blood and Lymph Conditions

Immune System Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

This is a single arm, open-label, multicenter phase I study with a dose escalation and an expansion segment.

For the Dose escalation segment, 3-9 patients per dose cohort will receive:

* Dose level 1: Low
* Dose level 2: Medium
* Dose level 3: High

For the expansion segment, additional patients may be enrolled until a maximum of 20 patients have received the recommended dose

TEG002 cells are autologous T cells transduced with a specific γδTCR

TEG002

This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma patients.

The study will comprise of a Dose Escalation Segment and an Expansion Segment. The study consists of a screening period, leukapheresis of mononuclear cells, and conditioning chemotherapy, followed by TEG002. All subjects continue to be followed regularly for safety and efficacy assessments until 1 year after TEG002 administration.

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

A Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of TEG002 Infusion in Relapsed/Refractory Multiple Myeloma Patients

For the dose escalation segment: Safety determined by incidence of (S)AEs by type and grade, including the occurrence of dose-limiting toxicities (DLTs)

For the expansion segment: Confirmation of safety determined by the incidence of (S)AEs by type and grade

Feasibility of TEG002 generation in r/r MM patients as measured by the number of TEG002 products successfully generated in r/r MM patients

Safety \& Efficacy: TEG002 persistence measured by qPCR in blood in bone marrow over time

Safety \& Efficacy: TEG002 pharmacodynamics measured by the level of IL6 in serum over time

Safety \& Efficacy: TEG002 pharmacodynamics measured by the CRP level in serum over time

Safety \& Efficacy: TEG002 pharmacodynamics measured by the ferritin level in serum over time

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery	NCT01267305	Lung Neoplasms Esophageal Neop... Venous Thromboe...	Fondaparinux Nadroparin Calc... Nadroparin Calc...	18 Years -	Shanghai Zhongshan Hospital
The Impact of Different Anticoagulant Therapy on Hemorrhage and Coagulation After Thoracic Surgery	NCT01267305	Lung Neoplasms Esophageal Neop... Venous Thromboe...	Fondaparinux Nadroparin Calc... Nadroparin Calc...	18 Years -	Shanghai Zhongshan Hospital
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients	NCT04688853	Multiple Myelom... Multiple Myelom... Multiple Myelom...	TEG002	18 Years -	Gadeta B.V.

Spots Global Cancer Trial Database for teg

Every month we try and update this database with for teg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for teg

Every month we try and update this database with for teg cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for teg cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.